FL
Therapeutic Areas
Infant Bacterial Therapeutics AB Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IBP-9414 | Prevention of Necrotizing Enterocolitis (NEC) and improvement of feeding tolerance in very low birth weight preterm infants | Phase 3 |
Leadership Team at Infant Bacterial Therapeutics AB
SS
Staffan Strömberg
Chief Executive Officer (CEO)
MG
Mikael G. Engdahl
Chief Financial Officer (CFO)
CS
Catharina Svanborg
Chairman of the Board
JA
Jan Andersson
Board Member
JJ
Jonas Jendi
Board Member
KW
Karin Wingstrand
Board Member